Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $37 Price Target

HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $37 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vericel (NASDAQ:VCEL) with a Buy and maintains $37 price target.

byBenzinga Newsdesk

January 27, 2023

1 minute read

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vericel (NASDAQ:VCEL) with a Buy and maintains $37 price target.

British Chip Designer Arm Proposes To Charge More For Chip Designs To Boost Topline Ahead Of IPO

By Anusuya Lahiri

March 23, 8:46 AM

British chip designer Arm Ltd is seeking to raise prices for its chip designs.

ERIC

Daré Bioscience’s Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause

By Vandana Singh

October 17, 10:58 AM

Daré Bioscience Inc (NASDAQ:DARE) announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal…

DARE

News

Everest Consolidator Acquisition Corporation Receives NYSE Notice Regarding Delayed Form 10-Q Filing

By Benzinga Newsdesk

November 28, 5:24 PM

Everest Consolidator Acquisition Corporation (the "Company") today announced that on November 21, 2023 it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") indicating that the Company is not

MNTN

Netsol Technologies Q2 EPS $(0.19) Down From $0.13 YoY, Sales $12.40M Down From $15.47M YoY

By Bill Haddad

February 14, 9:36 AM

Netsol Technologies (NASDAQ:NTWK) reported quarterly losses of $(0.19) per share. This is a 246.15 percent decrease over earnings of $0.13 per share from the same period last year. The company reported $12.40 million in

NTWK

HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $37 Price Target

Related Posts

British Chip Designer Arm Proposes To Charge More For Chip Designs To Boost Topline Ahead Of IPO

Daré Bioscience’s Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause

Everest Consolidator Acquisition Corporation Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Netsol Technologies Q2 EPS $(0.19) Down From $0.13 YoY, Sales $12.40M Down From $15.47M YoY